₹ 1,062.25 Cr
2.25%
BSE Healthcare TRI
INF789F01695
5000.0
1000.0
500
Mr. Kamal Gada FM 1,Not Applicable FM 2,Not Applicable FM 3
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
UTI Healthcare Fund - Regular Plan - Growth Option | 20.03 | 26.79 | 22.62 |
Benchmark | - | - | - |
Equity
Debt
Others
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Company | Holdings (%) |
---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 10.44 |
CIPLA LIMITED EQ NEW FV RS.2/- | 5.52 |
Dr. Reddys Laboratories Ltd | 4.66 |
PROCTER & GAMBLE HEALTH LIMITED EQ | 4.34 |
AJANTA PHARMA LIMITED EQ NEW FV RS. 2/- | 4.09 |
GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | 3.78 |
APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 3.65 |
DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 3.49 |
FORTIS HEALTHCARE LIMITED. EQ | 3.09 |
ERIS LIFESCIENCES LIMITED EQ NEW FV RE. 1/- | 3.04 |
Sector | Holdings (%) |
---|---|
Healthcare | 97.34 |